Johns Hopkins Pediatric Specialty Clinic

Baltimore, Maryland 21287

1 studies enrolling now · 1 studies all time

What they study most

Autosomal Recessive Polycystic Kidney (ARPKD)

Studies at this site

• A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD) — Recruiting now